CC-115 (hydrochloride)

1300118-55-1

C16H17ClN8O

DMSO : >= 30 mg/mL (80.47 mM)

PI3K/Akt/mTOR; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

CC-115 hydrochloride is a potent and dual DNA-PK and mTOR kinase inhibitor with IC₅₀s of 13 nM and 21 nM, respectively. CC-115 blocks both mTORC1 and mTORC2 signaling. IC50 & Target: IC50: 21 nM (mTOR), 13 nM (DNA-PK), 852 nM (PI3Kalpha)^[1]
mTORC1, mTORC2^[1] In Vitro: CC-115 inhibits PC-3 cells proliferation with an IC₅₀ of 138 nM. In a kinase selectivity assessment against a panel of 250 protein kinases at 3 uM, only one kinase other than mTOR kinase is identified with more than 50% inhibition (cFMS 57%, IC₅₀=2.0 uM). Of the PI3K related kinases (PIKKs) tested, CC-115 proves to be equipotent against DNA PK (IC₅₀=15 nM) and demonstrates 40 to >1000 fold selectivity against the remaining PIKKs tested; PI3K-alpha (IC₅₀=0.85 uM), ATR (50% inhibition at 30 uM) and ATM (IC₅₀>30 uM). The IC₅₀ values for CC-115 are >10 uM against a panel of CYP enzymes and >33 uM for the hERG (human ether-a-go-go-related gene) ion channel. When screened in a single point assay at 10 uM against a Cerep receptor and enzyme panel only one target is inhibited >50% (PDE3, IC₅₀=0.63 uM)^[1]. In Vivo: CC-115 hydrochloride shows good in vivo PK profiles across multiple species with 53%, 76% and ca.100% oral bioavailability in mouse, rat and dog, respectively. CC-115 is tested at lower doses of 0.25, 0.5 and 1 mg/kg bid or 1 mg/kg qd, with observed corresponding tumor volume reductions of 46%, 57%, 66% and 57% respectively. CC-115 sustains inhibition though 24 hours. At the 1 mg/kg dose CC-115 shows significant inhibition at 1 and 3 hours, CC-115 demonstrating inhibition through 10 hours. CC-115 is evaluated using both once (qd) and twice (bid) daily dosing schedules^[1].